|
1
|
Mohamed NA, Ahmetaj-Shala B, Duluc L, Mackenzie LS, Kirkby NS, Reed DM, Lickiss PD, Davies RP, Freeman GR, Wojciak-Stothard B, Chester AH, El-Sherbiny IM, Mitchell JA, Yacoub MH. A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension. J Cardiovasc Transl Res 2016; 9:162-4. [PMID: 26960567 PMCID: PMC4830862 DOI: 10.1007/s12265-016-9684-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Accepted: 02/17/2016] [Indexed: 01/25/2023]
Abstract
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effects have hampered the clinical use of NO in PAH. In an attempt to circumvent these major limitations, we have developed a new NO-nanomedicine formulation. The formulation was based on hydrogel-like polymeric composite NO-releasing nanoparticles (NO-RP). The kinetics of NO release from the NO-RP showed a peak at about 120 min followed by a sustained release for over 8 h. The NO-RP did not affect the viability or inflammation responses of endothelial cells. The NO-RP produced concentration-dependent relaxations of pulmonary arteries in mice with PAH induced by hypoxia. In conclusion, NO-RP drugs could considerably enhance the therapeutic potential of NO therapy for PAH.
Collapse
Affiliation(s)
- Nura A Mohamed
- Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK
- Heart Science Centre, Imperial College, Harefield, Uxbridge, UB9 6JH, UK
- Qatar Foundation Research and Development Division, Doha, Qatar
| | - Blerina Ahmetaj-Shala
- Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK
| | - Lucie Duluc
- Department of Experimental Medicine and Toxicology, Hammersmith Campus, Imperial College London, Du Cane Road, London, W12 0NN, UK
| | - Louise S Mackenzie
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK
| | - Nicholas S Kirkby
- Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK
| | - Daniel M Reed
- Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK
| | - Paul D Lickiss
- Synthesis Section, Department of Chemistry, Imperial College London, South Kensington, London, SW7 2AZ, UK
| | - Robert P Davies
- Synthesis Section, Department of Chemistry, Imperial College London, South Kensington, London, SW7 2AZ, UK
| | - Gemma R Freeman
- Synthesis Section, Department of Chemistry, Imperial College London, South Kensington, London, SW7 2AZ, UK
| | - Beata Wojciak-Stothard
- Department of Experimental Medicine and Toxicology, Hammersmith Campus, Imperial College London, Du Cane Road, London, W12 0NN, UK
| | - Adrian H Chester
- Heart Science Centre, Imperial College, Harefield, Uxbridge, UB9 6JH, UK
| | - Ibrahim M El-Sherbiny
- Center for Materials Science, Zewail City, Sheikh, Zayed District, 12588, 6th of October City, Giza, Egypt
| | - Jane A Mitchell
- Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK
| | - Magdi H Yacoub
- Heart Science Centre, Imperial College, Harefield, Uxbridge, UB9 6JH, UK.
| |
Collapse
|